All In Biotech

BLA 103532 · Genentech

Pulmozyme

Dornase Alfa · Recombinant Human Deoxyribonuclease 1

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Dec 30, 1993

Approved uses

4

Original approval plus efficacy supplements

Registered trials

53

11 Phase 3, 7 recruiting

FAERS reports

19,634

13,482 serious, 827 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 17, 2025.

PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. PULMOZYME is a recombinant DNase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. ( 1 )

Mechanism: PULMOZYME is recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, PULMOZYME hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 12, 2014 Supplement 5175 · Efficacy LetterLabel
  • Feb 24, 1998 Supplement 1025 · Efficacy
  • Nov 27, 1996 Supplement 1018 · Efficacy
  • Dec 30, 1993 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • PULMOZYME · DORNASE ALFA 1MG/ML · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dornase Alfa" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infective pulmonary exacerbation of cystic fibrosis2,316
  • cystic fibrosis1,776
  • hospitalisation1,320
  • pneumonia1,308
  • cough1,000
  • off label use975
  • infection950
  • no adverse event944
  • dyspnoea926
  • condition aggravated623
  • headache548
  • pulmonary function test decreased494

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
200515
200618
200725
200844
200928
201085
2011277
2012217
2013240
2014438
2015793
20161,160
20171,288
20182,093
20193,972
20203,601
20211,263
20221,076
2023848
20241,040
2025662
2026435

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pulmozyme (Dornase Alfa)

2024 spending

$2.0M

Beneficiaries

100

443 claims

Per beneficiary

$20,465

$50.07 per unit

View as table
YearSpending
2020$2,236,443
2021$1,906,841
2022$2,050,467
2023$2,299,698
2024$2,046,484

Part B: Pulmozyme (Dornase Alfa) · HCPCS J7639

2024 spending

$23.2M

Beneficiaries

892

5,623 claims

Per beneficiary

$25,988

2024 ASP limit $52.76 per unit

View as table
YearSpending
2020$31,924,225
2021$29,490,764
2022$26,071,831
2023$24,138,838
2024$23,180,890

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 82 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.